Showing 3441-3450 of 6039 results for "".
- Sarecycline Monotherapy Delivers in Real-World Acne Studyhttps://practicaldermatology.com/news/sarecycline-monotherapy-delivers-in-real-world-acne-study/2484121/A post hoc analysis of the PROSES study found that oral sarecycline monotherapy is as effective as combination therapy with topicals in treating moderate-to-severe acne vulgaris (AV), based on 12-week outcomes from a real-world U.S. cohort presented by Dr. Hilary B
- Deucravacitinib Provides Superior Real-World PsO Skin Clearance at 6 Monthshttps://practicaldermatology.com/news/deucravacitinib-provides-superior-real-world-pso-skin-clearance-at-6-months/2484117/Real-world data from the North American cohort of the RePhlect registry confirm that deucravacitinib provides significantly better skin clearance than apremilast at 6 months in adults with moderate-to-severe plaque psoriasis.
- Dr. Woolery-Lloyd Appointed Program Development Advisor for Skin of Color Updatehttps://practicaldermatology.com/news/dr-woolery-lloyd-appointed-program-development-advisor-for-skin-of-color-update/2484015/Heather Woolery-Lloyd, MD, FAAD, has been appointed program development advisor for Skin of Color Update, the nation’s largest medical education event focused on dermatologic care for patients with skin of color. Dr. Woolery-Lloyd serves as director of the Skin of Color Division at the Uni
- IFPA Highlights Patient Voices in Global Health Policy at UN Panelhttps://practicaldermatology.com/news/ifpa-highlights-patient-voices-in-global-health-policy/2483540/The International Federation of Psoriatic Disease Associations (IFPA) issued a call to global policymakers to recognize psoriatic disease as a serious noncommunicable disease (NCD) with system-wide implications at the 80th UN General Assembly in New York.
- From EADV: Rezpegaldesleukin Effective Through 24 Weeks in REZOLVE-AD Trialhttps://practicaldermatology.com/news/from-eadv-rezpegaldesleukin-effective-through-24-weeks-in-rezolve-ad-trial/2483465/New data from the REZOLVE-AD presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress demonstrated that investigational IL-2 pathway agonist rezpegaldesleukin sustained effect beyond the 16-week induction period in patients with moderat
- From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Programhttps://practicaldermatology.com/news/from-eadv-povorcitinib-maintains-efficacy-through-24-weeks-in-hs-phase-3-data/2483429/New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025
- Long-Term Data Support Safety of Upadacitinib in Women With AD Using OCPshttps://practicaldermatology.com/news/long-term-data-support-safety-of-upadacitinib-in-women-with-ad-using-ocps/2483285/Upadacitinib maintains a favorable benefit–risk profile in women with moderate-to-severe atopic dermatitis (AD), regardless of oral contraceptive pill (OCP) or hormone replacement therapy (HRT) use, according to long-term safety data presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) C
- Bimekizumab Outperforms IL-17 Inhibitors in Real-World Psoriasis Studyhttps://practicaldermatology.com/news/bimekizumab-shows-edge-over-il-17-inhibitors-in-polish-real-world-psoriasis-study/2482980/Bimekizumab demonstrated a faster and more robust response than secukinumab and ixekizumab in a real-world cohort of Polish patients with moderate-to-severe plaque psoriasis. Researchers conducted a retrospective analysis fro
- Switching Biologics for Psoriasis May Improve Outcomes Without Added Risk: Studyhttps://practicaldermatology.com/news/switching-biologics-for-psoriasis-may-improve-outcomes-without-added-risk-study/2476064/Plaque psoriasis patients who are unresponsive to initial biologics may derive benefit from switching to another drug class, according to a new meta-analysis of 24 randomized controlled trials (RCTs). The review looked at da
- Study: Ustekinumab Shows Durability in Real-World Psoriasis Biologic Sequencing Studyhttps://practicaldermatology.com/news/study-ustekinumab-shows-durability-in-real-world-psoriasis-biologic-sequencing-study/2476000/Ustekinumab (Stelara) was associated with the longest treatment duration among biologics used for moderate-to-severe psoriasis, according to results from a recent retrospective real-world analysis. Researchers evaluated health